It is widely known that racial inequalities exist when it comes to the survival rate of cancer. A new study by researchers at the Duke Cancer Institute is a new study: Why?
In a study published on Friday afternoon in the Journal of Clinical Oncology, researchers examined the effects of chemotherapy in triple-negative breast cancer patients.
According to the American Cancer Society, triple-negative breast cancer is aggressive and eats for 15% of all breast cancer.
Dr. with Duke Cancer Institute. Maggi Dinom said, “We define our breast cancer subtypes by expression of three main markers: estrogen receptor, progesterone receptor and a third protein called HER2.” “When you are negative for those three, you are classified as being triple-negative breast cancer.”
Women under 40, as well as Hispanic and black women are at greater risk.
Senior writer of the study, Dinom, explained that chemotherapy is widely accepted as the first phase in treatment schemes for women after diagnosis. He said this is because there is no “specific, effective targeted treatment for such breast cancer.”
This made triple-negative breast cancer a good illness to make the study the basis because the remedies followed a similar course of action regardless of ethnicity.
“The purpose of our study was to see and see if there was any difference in the response to treatment on the basis of the race, because we have seen the difference in results in patients,” Dinom said.
The results of the study showed that chemotherapy was not effective throughout the board.
“It seems that the reaction to treatment, and then the overall survival, is actually different from the breed and ethnicity,” shared by the dinom.
According to the study, Hispanic women had the best response rate of all with chemotherapy, which effectively cleaned the tumor in 33% of patients. Chemo 31% was effective in white women; It was 29% effective for Asian women. Black women had the lowest response rate at 27%.
Dinom explained that this may mean that tumors themselves may vary biologically in different races.
“I think the importance, is that we need to understand a little more about the biology of the tumor: what makes them different? And, what can it pave the way for future research that allows us to find more effective treatment?” Inquiries.
He said, “Due to all clinical trials that led to the development of these regime of treatment for women with triple-negative breast cancer, were mainly focused on white women. Minority women were historically reduced. This data comes from those tests, so we had no really way to assess: ‘Does this therapy do equal work for all women?’ ,
Dinom shared that he believes that breast cancer has “led the route” in terms of standardizing chemotherapy as the first step in treatment plans. This is the reason that she thinks that on the basis of race, further studies should be done in other cancer to find out the idea of various tumors.
“Our hope for future research based on the results of our study is to really understand the biological differences present in these cancer sub -factories so that we can really get more effective treatment for women who have this aggressive cancer,” Dinom said.
He said, “If our problem is that we are not able to receive that complete response for women and that is why they are not good in terms of survival, then we really need to work on finding that effective treatment based on individual patients. A size is not fit for all, and we need to move forward in the context of personal care and personal medicine and understand those differences.”
Triple-negative breast cancer is usually one of the cancer found in mammograms.
Symptoms may include breast inflammation, skin dimpling, breast pain, changes in nipple, discharge and inflammatory lymph nodes.
Annual screening is recommended for women starting at the age of 40. People with known family history of the disease are advised to talk with the doctor as the screening can be recommended soon. outcome